This research study is a Phase II clinical trial. Phase II clinical trials test the safety
and effectiveness of an investigational intervention to learn whether the intervention works
in treating a specific disease. "Investigational" means that the intervention is being
studied.
Eribulin works by interfering with cancer cell division, growth, and spread.
The goal of this research study is to evaluate inflammatory breast cancer's response to
treatment with eribulin followed by AC chemotherapy (Cohort A) and also the response to
treatment with AC followed by Eribulin (Cohort B) when given as a preoperative chemotherapy
treatment for participants with HER2 negative inflammatory breast cancer.
Inclusion Criteria:
-Participants must have histologically confirmed invasive breast cancer. All histologic
subtypes are eligible.
-- Patients must NOT have HER2 positive status based on ASCO/CAP guidelines defined as: IHC
3+ based on circumferential membrane staining that is complete, intense and/or
FISH positive based on one of the three following criteria:
Single-probe average HER2 copy number ≥ 6.0 signals/cell; OR Dual-probe HER2/CEP17 ratio
<2.0 with an average HER2 copy number ≥ 6.0 signals/cell; OR Dual-probe HER2/CEP17 ratio
≥2.0
- Age ≥18 years. Because no dosing or adverse event data are currently available on the
use of eribulin in participants <18 years of age, children are excluded from this
study
- ECOG performance status ≤1 (Karnofsky ≥70%)
- Participants must have normal organ and marrow function as defined below:
- leukocytes ≥3,000/mcL
- absolute neutrophil count ≥1,500/mcL
- platelets ≥100,000/mcL
- total bilirubin within normal institutional limits
- AST(SGOT)/ALT(SGPT) ≤2.5 × institutional upper limit of normal creatinine ≤1.5 ×
institutional upper limit of normal
--- OR
- creatinine clearance ≥60 mL/min/1.73 m2 for participants with creatinine levels
above institutional normal.
- Patients must have the clinical diagnosis of inflammatory breast cancer.
- Patients must be without evidence of visceral or bone involvement with metastatic
cancer on physical exam or any diagnostic study. Extensive nodal involvement (distant
or regional) is allowed.
- LVEF > 50% calculated by echocardiogram (ECHO)
- Patients may have bilateral breast cancer so long as one breast meets criteria for
inflammatory breast cancer, and the breast with inflammatory breast cancer has never
received prior therapy.
- The effects of eribulin on the developing human fetus are unknown. For this reason and
because other therapeutic agents used in this trial are known to be teratogenic, women
of child-bearing potential and men must agree to use adequate contraception (hormonal
or barrier method of birth control; abstinence) prior to study entry and for the
duration of study participation. Should a woman become pregnant or suspect she is
pregnant while she or her partner is participating in this study, she should inform
her treating physician immediately. Men treated or enrolled on this protocol must also
agree to use adequate contraception prior to the study, for the duration of study
participation, and 4 months after completion of chemotherapy administration.
- Ability to understand and the willingness to sign a written informed consent document.
- Both men and women of all races and ethnic groups are eligible for this trial. Because
breast cancer predominantly affects females, it is anticipated that male enrollment
will be < 5% of the overall study population.
Exclusion Criteria:
- Participants who are receiving any other investigational agents.
- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to eribulin or other agents used in study.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements.
- Pregnant women are excluded from this study because eribulin is an agent with the
potential for teratogenic or abortifacient effects. Because there is an unknown but
potential risk for adverse events in nursing infants secondary to treatment of the
mother with eribulin, breastfeeding should be discontinued if the mother is treated
with eribulin. These potential risks may also apply to other agents used in this
study.
- HIV-positive participants on combination antiretroviral therapy are ineligible because
of the potential for pharmacokinetic interactions with eribulin. In addition, these
participants are at increased risk of lethal infections when treated with
marrow-suppressive therapy. Appropriate studies will be undertaken in participants
receiving combination antiretroviral therapy when indicated.
- A baseline corrected QT interval of > 470 ms.
- Individuals with a history of a different malignancy are ineligible except for the
following circumstances. Individuals with a history of other malignancies are eligible
if they have been disease-free for at least 3 years and are deemed by the investigator
to be at low risk for recurrence of that malignancy. Individuals with the following
cancers are eligible if diagnosed and treated within the past 3 years: cervical cancer
in situ, and basal cell or squamous cell carcinoma of the skin.
- Patients may not have received eribulin, paclitaxel, doxorubicin, or cyclophosphamide
as anti-neoplastic therapy.
